Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FP 1096

Drug Profile

FP 1096

Alternative Names: Endometriosis treatment - FemmePharma; FP1096; PARDEL™ endometriosis treatment - FemmePharma

Latest Information Update: 23 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FemmePharma; KV Pharmaceutical Company
  • Developer FemmePharma
  • Class Hormones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Endometriosis

Most Recent Events

  • 12 Jun 2014 Discontinued - Phase-III for Endometriosis in USA (Vaginal)
  • 29 May 2014 KV Pharmaceutical is now called Lumara Health
  • 08 Sep 2009 No development reported - Phase-III for Endometriosis in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top